A role for WISP2 in colorectal cancer cell invasion and motility

Cancer Genomics and Proteomics

Volumn 10, Issue 4, 2013, Pages 187-196

  Frewer, Kathryn A ^a   Sanders, Andrew J ^a   Owen, Sioned ^a   Frewer, Natasha C ^a   Hargest, Rachel ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cell invasion; Cell motility; Colorectal cancer; WISP2

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; PROTEIN; PROTEIN INHIBITOR; RIBOZYME; UNCLASSIFIED DRUG; WNT1 INDUCIBLE SIGNALLING PATHWAY PROTEIN 2;

ARTICLE; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL STRAIN CACO 2; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE MAMMARY TUMOR ONCOVIRUS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; UPREGULATION; WNT SIGNALING PATHWAY;

MOUSE MAMMARY TUMOR VIRUS;

EID: 84882412943     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell 147: 275-292, 2011.
3. Zuo GW, Kohls CD, He BC, Chen L, Zhang W, Shi Q, Zhang BQ, Kang Q, Luo J, Luo X, Wagner ER, Kim SH, Restegar F, Haydon RC, Deng ZL, Luu HH, He TC and Luo Q: The CCN proteins: Important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol 25: 795-806, 2010.
4. Davies SR, Davies ML, Sanders A, Parr C, Torkington J and Jiang WG: Differential expression of the CCN family member WISP1, WISP2 and WISP3 in human colorectal cancer and the prognostic implications. Int J Oncol 36: 1129-1136, 2010.
5. Banerjee S, Saxena N, Sengupta K, Tawfik O, Mayo MS and Banerjee SK: WISP2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 5: 63-73, 2003.
6. Fritah A, Saucier C, De Wever O, Bracke M, Bieche I, Lidereau R, Gespach C, Drouot S, Redeuilh G and Sabbah M: Role of WISP2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 28: 1114-1123, 2008.
7. Tian C, Zhou ZG, Meng WJ, Sun XF, Yu YY, Li L, Luo HZ, Yang L, Zhou B and Gu J: Overexpression of connective tissue growth factor WISP1 in Chinese primary rectal cancer patients. World J Gastroenterol 13: 3878-3882, 2007.
8. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D and Levine AJ: WISP genes are members of the connective tissue growth factor family that are up-regulated in WNT-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA 95: 14717-14722, 1998.
9. Khor TO, Gul YA, Ithnin H and Seow HF: A comparative study of the expression of WNT-1, WISP1, survivin and cyclin-D1 in colorectal carcinoma. Int J Colorectal Dis 21: 291-300, 2006.
10. Ray G, Banerjee S, Saxena NK, Campbell DR, Van Veldhuizen P and Banerjee SK: Stimulation of MCF-7 tumor progression in athymic nude mice by 17β-estradiol induces WISP2/CCN5 expression in xenografts. A novel signaling molecule in hormonal carcinogenesis, Oncol Rep 13: 445-448, 2005.
11. Hashimoto Y, Singh R, Munoz D and Lokeshwar B: WNT singaling protein (WISP2/CCN5) stimulates angiogenesis and invasion in prostate cancer. Journal of Urology 185: e512, 2011.
12. Cervello M, Giannitrapani L, Labbozzetta M, Notarbartolo M, D'Alessandro N, Lampiasi N, Azzolina A and Montalto G: Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann NY Acad Sci 1028: 432-439, 2004.
13. Dhar G, Mehta S, Banerjee S, Gardner A, McCarty BM, Mathur SC, Campbell DR, Kambhampati S and Banerjee SK: Loss of WISP2/CCN5 signaling in human pancreatic cancer: A potential mechanism for epithelial mesenchymal transition. Cancer Lett 254: 63-70, 2007.
14. Kouzu Y, Uzawa K, Kato M, Higo M, Nimura Y, Harada K, Numata T, Seki N, Sato M and Tanzawa H: WISP2 expression in human salivary gland tumors. Int J Mol Med 17: 567-573, 2006.
15. Banerjee S, Dhar G, Haque I, Kambhampati S, Mehta S, Sengupta K, Tawfik O, Phillips TA and Banerjee SK: CCN5/WISP2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res 68: 7606-7612, 2008.
16. Banerjee SK and Banerjee S: CCN5/WISP2: A micromanager of breast cancer progression. J Cell Commun Signal 6: 63-71, 2012.
17. Sabbah M, Prunier C, Ferrand N, Megalophonos V, Lambein K, De Wever O, Nazaret N, Lachuer J, Dumont S and Redeuilh G: CCN5, a novel transcriptional repressor of the transforming growth factor beta signaling pathway. Mol Cell Biol 31: 1459-1469, 2011.
18. Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ and Banerjee SK: Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP2. Cancer Res 68: 4580-4587, 2008.
19. Al-Rawi MA, Watkins G, Mansel RE and Jiang WG: The effects of interleukin-7 on the lymphangiogenic properties of human endothelial cells. Int J Oncol 27: 721-730, 2005.
20. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE and Puntis MC: Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res 55: 5043-5048, 1995.
21. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF and Puntis MC: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br J Cancer 71: 744-752, 1995.
22. Fernando HS, Sanders AJ, Kynaston HG and Jiang WG: WAVE3 is associated with invasiveness in prostate cancer cells. Urol Oncol 28: 320-327, 2010.
23. Rosen EM, Jaken S, Carley W, Luckett PM, Setter E, Bhargava M and Goldberg ID: Regulation of motility in bovine brain endothelial cells. J Cell Physiol 146: 325-335, 1991.
24. 2+. Exp Cell Res 220: 424-433, 1995.
25. Banerjee S, Sengupta K, Saxena NK, Dhar K and Banerjee SK: Epidermal growth factor induces WISP2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res 3: 151-162, 2005.
26. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Patterns of MMP2 and MMP9 expression in human cancer cell lines. Oncol Rep 21: 1323-1333, 2009.
27. Dong W, Li H, Zhang Y,Yang H, Guo M, Li L and Liu T: Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin 43: 840-848 2011.
28. Zeng ZS, Shu WP, Cohen AM and Guillem JG: Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: Evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 8: 144-148, 2002.
29. Handeli S and Simon JA: A small-molecule inhibitor of TCF/β-catenin signaling down-regulates PPARγ and PPARδ activities. Mol Cancer Ther 7: 521-529, 2008.
30. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C and Lum L: Small molecule-mediated disruption of WNT-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5: 100-107, 2009.
31. Brabletz T, Jung A, Dag S, Hlubek F and Kirchner T: β-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155: 1033-1038, 1999.
32. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P and Matrisian LM: The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 18: 2883-2891, 1999.